1. J Pers Med. 2022 Jun 29;12(7):1074. doi: 10.3390/jpm12071074.

An Integrated Approach for the Early Detection of Endometrial and Ovarian 
Cancers (Screenwide Study): Rationale, Study Design and Pilot Study.

Peremiquel-Trillas P(1)(2)(3), Paytubi S(1), Pelegrina B(1), Frias-Gomez 
J(1)(2)(3), Carmona Á(1), Martínez JM(4), de Francisco J(5), Benavente Y(1)(3), 
Barahona M(4), Briansó F(6)(7), Canet-Hermida J(8)(9), Caño V(5), Vidal 
A(9)(10), Zanca A(10), Baixeras N(10), Rodríguez A(10), Fernández-Gonzalez S(4), 
Dueñas N(8)(9), Càrdenas L(11), Aytés Á(12), Bianchi I(13), Pavón MÀ(1)(3), 
Reventós J(14), Capellà G(8)(9), Gómez D(1), Diaz M(1)(3), Ponce J(4), Brunet 
J(8)(9)(15), Matias-Guiu X(9)(10), Bosch FX(1)(3)(16), de Sanjosé S(3)(17), 
Alemany L(1)(3), Pineda M(8)(9), Marin F(8)(9), Costas L(1)(3).

Author information:
(1)Cancer Epidemiology Research Programme, Catalan Institute of Oncology, 
IDIBELL, l'Hospitalet de Llobregat, 08908 Barcelona, Spain.
(2)Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
(3)Consortium for Biomedical Research in Epidemiology and Public 
Health-CIBERESP, Carlos III Institute of Health, 28029 Madrid, Spain.
(4)Department of Gynecology, IDIBELL, Hospital Universitari de Bellvitge, 
Hospitalet de Llobregat, 08908 Barcelona, Spain.
(5)Department of Anesthesiology, IDIBELL, Hospital Universitari de Bellvitge, 
Hospitalet de Llobregat, 08908 Barcelona, Spain.
(6)Department of Genetics, Microbiology and Statistics, Universitat de 
Barcelona, 08028 Barcelona, Spain.
(7)Roche Diagnostics, Sant Cugat del Vallès, 08174 Barcelona, Spain.
(8)Hereditary Cancer Group, ONCOBELL Program, Catalan Institute of Oncology, 
IDIBELL, L'Hospitalet, 08908 Barcelona, Spain.
(9)Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute 
of Health, 28029 Madrid, Spain.
(10)Department of Pathology, IDIBELL, Hospitalet de Llobregat, Hospital 
Universitari de Bellvitge, 08907 Barcelona, Spain.
(11)Department of Gynecology and Obstetrics, Hospital Universitari Dr. Josep 
Trueta, 17007 Girona, Spain.
(12)Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Hospitalet 
de Llobregat, 08908 Barcelona, Spain.
(13)ASSIR Delta, Serveis d'Atenció Primària Delta del Llobregat, Direcció 
d'Atenció Primària Costa de Ponent, Gerència Territorial Metropolitana Sud, 
Institut Català de la Salut, 08006 Barcelona, Spain.
(14)Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, 
08017 Barcelona, Spain.
(15)Medical Oncology Department, Catalan Institute of Oncology, Doctor Josep 
Trueta Girona University Hospital, 17007 Girona, Spain.
(16)Universitat Oberta de Catalunya, 08018 Barcelona, Spain.
(17)Consultant, National Cancer Institute, Bethesda, MA 20814, USA.

Screenwide is a case-control study (2017−2021) including women with incident 
endometrial and ovarian cancers (EC and OC), BRCA1/2 and MMR pathogenic variant 
carriers, and age-matched controls from three centers in Spain. Participants 
completed a personal interview on their sociodemographic factors, occupational 
exposure, medication, lifestyle, and medical history. We collected biological 
specimens, including blood samples, self-collected vaginal specimens, cervical 
pap-brush samples, uterine specimens, and, when available, tumor samples. The 
planned analyses included evaluation of the potential risk factors for EC/OC; 
evaluation of molecular biomarkers in minimally invasive samples; evaluation of 
the cost-effectiveness of molecular tests; and the generation of predictive 
scores to integrate different epidemiologic, clinical, and molecular factors. 
Overall, 182 EC, 69 OC, 98 BRCA pathogenic variant carriers, 104 MMR pathogenic 
variant carriers, and 385 controls were enrolled. The overall participation rate 
was 85.7%. The pilot study using 61 samples from nine EC cases and four controls 
showed that genetic variants at the variant allele fraction > 5% found in tumors 
(n = 61 variants across the nine tumors) were detected in paired endometrial 
aspirates, clinician-collected cervical samples, and vaginal self-samples with 
detection rates of 90% (55/61), 79% (48/61), and 72% (44/61) by duplex 
sequencing, respectively. Among the controls, only one somatic mutation was 
detected in a cervical sample. We enrolled more than 800 women to evaluate new 
early detection strategies. The preliminary data suggest that our methodological 
approach could be useful for the early detection of gynecological cancers.

DOI: 10.3390/jpm12071074
PMCID: PMC9324683
PMID: 35887570

Conflict of interest statement: The authors received supplies from IDT and Roche 
Diagnostics at 50% discount. Laura Costas received speaking honoraria from Roche 
Diagnostics. Ferran Briansó has an employment relationship with Roche 
Diagnostics. Idibell and Roche Diagnostics signed a contract to collaborate in 
the development of the bioinformatics pipeline of the project. The authors do 
not have other conflicts of interest to declare.